Clinical Trials
-
Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
A Scientific Sessions panel shared new data from the VESPER trials. The long half-life of berobenatide makes investigators optimistic about its potential for monthly dosing.
-
Positive data from multiple amylin trials draw focus to novel therapeutic mechanism
Investigators, including Carel le Roux, MBChB, FRCP, FRCPath, PhD, discussed findings from monotherapy and combination trials with the pancreatic beta cell hormone. “Not only are these weight loss drugs, these are also health-gain drugs,” Dr. le Roux said.
-
Dual GLP-1/GIP receptor agonist improves glycemic management and weight loss in adults living with type 1 diabetes and obesity
Klara Klein, MD, PhD, and other researchers shared results from a phase 2, double-blind, randomized study of acmopatide. Study participants also experienced improvements in blood pressure and insulin dosing.
-
Automated insulin delivery demonstrates efficacy in glycemic management in the hospital
Francisco Pasquel, MD, MPH, and other panelists presented new data from the AIDING trial, which compared automated inulin delivery to multiple daily injections combined with continuous glucose monitoring in individuals with type 1 diabetes or type 2 diabetes during hospitalization.
-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.
-
REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes
Donna Ryan, MD, and other panelists reported on new data from phase 3 trials evaluating the combination of cagrilintide, which mimics amylin, and semaglutide, a glucagon-like peptide-1 receptor agonist, in adults.
-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that meets health needs without the logistical challenges of current treatments, said Rodolfo J. Galindo, MD.
-
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults. Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, and Vanita R. Aroda, MD, shared the latest study data.
-
Outstanding Scientific Achievement Award lecturer highlights evolution of unimolecular therapies
Timo D. Müller, PhD, shared his insights on hormonal control of metabolism by glucose-dependent insulinotropic polypeptide (GIP) and next-generation incretin-based polyagonists during a session recognizing his contributions to diabetes and metabolic research.